# UroGen Pharma Ltd. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/UroGen Pharma Ltd.). ## Overview UroGen Pharma Ltd. is a biopharmaceutical company focused on urothelial and specialty cancers, built around its proprietary RTGel reverse-thermal hydrogel platform. The company develops and commercializes local therapies for urinary tract cancers, including approved products Jelmyto and Zusduri, and maintains a pipeline of investigational oncology candidates. ## Products & services • Jelmyto (mitomycin) for pyelocalyceal solution • Zusduri (mitomycin) for intravesical solution • RTGel reverse-thermal hydrogel drug-delivery platform • UGN-501 oncolytic virus program • Urothelial cancer commercialization and medical education services - **Commercial oncology products** (100%) — Approved therapies sold for non-muscle invasive urothelial cancers. - **Drug-delivery platform technology** (0%) — RTGel is used to extend local exposure of drugs in the urinary tract. - **Clinical-stage pipeline** (0%) — Investigational programs for additional urothelial and specialty cancers. - Jelmyto (mitomycin) for pyelocalyceal solution - Zusduri (mitomycin) for intravesical solution - RTGel reverse-thermal hydrogel drug-delivery platform - UGN-501 oncolytic virus program - Urothelial cancer commercialization and medical education services ## Customers UroGen sells primarily to physicians and healthcare providers treating urothelial cancer, especially urologists and oncology-focused practices. Access and reimbursement teams also interact with payers, pharmacies, and key accounts because adoption depends on formulary coverage, administration workflows, and patient eligibility. - **Urologists** (primary) — Prescribe Jelmyto and Zusduri for eligible urothelial cancer patients and drive account adoption. - **Oncology practices and cancer centers** (primary) — Use the products in specialty cancer care settings and support broader physician uptake. - **Payers and reimbursement stakeholders** (secondary) — Influence patient access through coverage, prior authorization, and reimbursement policies. - **Pharmacies and treatment sites** (secondary) — Prepare, dispense, and administer the product admixture and support clinical workflow. - Urologists treating low-grade UTUC and recurrent NMIBC - Oncology practices that prescribe and administer local therapies - Hospitals and outpatient centers that manage treatment workflows - Payers and reimbursement stakeholders influencing access - Mixing pharmacies that prepare Jelmyto admixture for use ## Geography UroGen is organized under Israeli law, with principal executive offices in Princeton, New Jersey, and employees in both the United States and Israel. Commercial activity is centered in the United States, where Jelmyto is marketed and where the company’s customer-facing organization is based. - **United States** (100%) — Commercial revenue is described as U.S.-based; no country split was disclosed. - Headquartered legally in Israel and operationally in Princeton, New Jersey - Commercial sales are concentrated in the United States - Employees are split between the U.S. and Israel - U.S. market access and reimbursement are central to adoption - International commercialization would likely rely on partners ## Strategy UroGen’s strategy centers on expanding commercialization of Jelmyto and launching Zusduri while advancing its pipeline in urothelial and specialty cancers. The company also uses partnerships and licensing selectively to extend its technology and reach outside the United States where appropriate. - **Commercialize approved products** (short-term) — Revenue and market presence depend on physician adoption and access for Jelmyto and Zusduri. - **Advance pipeline development** (medium-term) — Future growth depends on expanding the product portfolio beyond current approved therapies. - **Build commercialization partnerships outside the U.S.** (medium-term) — International markets may require local partners with established sales and distribution networks. - Expand adoption of Jelmyto in eligible urothelial cancer patients - Launch and scale Zusduri commercialization - Advance RTGel-based pipeline candidates such as UGN-501 - Use market access, education, and reimbursement support to drive uptake - Pursue ex-U.S. partnerships and licensing where commercialized ## Risks UroGen depends heavily on successful commercialization of a small number of products, so adoption, reimbursement, and physician acceptance are central risks. The business also faces typical biotech exposures around clinical development, manufacturing quality, single-source suppliers, intellectual property, and the need for additional financing. - **Commercial dependence on a limited product base** [high] — Most current revenue and strategic value depend on Jelmyto and Zusduri adoption. - **Financing risk** [high] — The company has a history of losses and may need external capital to support operations. - **Manufacturing and supply-chain risk** [high] — Pharmaceutical products rely on contract manufacturers and single-source suppliers. - **Regulatory and clinical development risk** [high] — Pipeline programs may fail to demonstrate safety, efficacy, or manufacturability. - **Reimbursement and physician adoption risk** [medium] — Specialty oncology products require coverage, formulary access, and workflow integration. - Dependence on Jelmyto and Zusduri commercialization - Need for additional financing to fund operations and development - Clinical trial and regulatory approval risk for pipeline assets - Single-source supplier and contract manufacturing exposure - Reimbursement and market-access risk for specialty oncology products ## Accounting Revenue is driven by product sales, so timing of shipments, chargebacks, rebates, and government-program reserves can materially affect reported results. Investors should also watch inventory write-offs, acquired-intangible or milestone-related obligations, debt accounting, and the judgment involved in estimating clinical and regulatory development costs. - **Net product revenue reserves** — Affects reported revenue and gross margin - **Inventory write-offs and unit-cost changes** — Affects cost of revenue - **Debt and prepaid forward obligation accounting** — Affects net loss and cash flow interpretation - **Acquired asset consideration and royalties** — Affects future expense recognition and contingent obligations - Product revenue net of chargebacks and government-program reserves - Inventory valuation and write-offs for commercial product supply - Debt accounting for Pharmakon borrowings and interest expense - Milestone and royalty obligations from acquired assets - Estimates for clinical, regulatory, and commercialization accruals --- *Last updated: 2026-04-29T05:06:29.891393+00:00*